Directorate Change
January 09 2003 - 5:30AM
UK Regulatory
RNS Number:9616F
Cambridge Antibody Tech Group PLC
09 January 2003
03/CAT/03
FOR IMMEDIATE RELEASE
10.30 GMT 05.30 EST 9 January 2002
For Further Information Contact: Weber Shandwick Square Mile (Europe)
Cambridge Antibody Technology Tel: +44 (0) 20 7067 0700
Tel: +44 (0) 1223 471 471 Kevin Smith
Peter Chambre, Chief Executive Officer Graham Herring
John Aston, Chief Financial Officer
Rowena Gardner, Director of Corporate
Communications
BMC Communications/The Trout Group
(USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCES
NEW NON-EXECUTIVE DIRECTOR
Cambridge, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) is
pleased to announce the appointment of Dr Peter Ringrose as a Non-Executive
Director to the Board, with effect from 10 February 2003.
Peter Ringrose has spent his whole 32-year career in the pharmaceutical industry
and, in particular, has many years' experience in drug discovery. He was most
recently Chief Scientific Officer and President of Bristol-Myers Squibb Research
Institute, Princeton, New Jersey, and a member of the Executive Committee of
Bristol-Myers Squibb Company, responsible for pharmaceutical R&D worldwide. He
retired from these roles in December 2002. Prior to joining Bristol-Myers Squibb
Company in 1997 he held a number of senior posts at Pfizer Inc, most recently
Senior Vice President Worldwide Drug Discovery and European Medicinal R&D. He
joined Pfizer UK in 1982. Previously, Peter held the post of Division Director
with Sandoz Research Institute (1979 - 1982) in Vienna, Austria, and held a
number of positions at Roche Research Division (1970 - 1979). He obtained a PhD
in Microbial Biochemistry in 1970 from Cambridge University, UK.
Peter Garland, CAT's Chairman, commented "We are delighted to welcome Peter
Ringrose as a Non-Executive Director of CAT. He is an eminent scientist and has
successfully led research and development organisations at the pinnacle of the
pharmaceutical industry. As such, he will add strength and significant expertise
to the Board and will make a significant contribution to CAT's development".
-ENDS-
Notes to Editors
Peter Ringrose - Biography and Details
* Education:
* 1964 - 1967 BA Hons Biochemistry, Cambridge University, UK
* 1967 - 1968 M.Phil Molecular Microbiology, Cambridge University, UK
* 1967 - 1970 PhD Microbial Biochemistry, Cambridge University, UK
* Career details:
* 1970 - 1979 Roche Research Division: Head of Biochemistry Department (1976
- 1978), Chairman of Anti-inflammatory projects (1978 - 1979);
* 1979 -1982 Sandoz Research Institute: Division Director;
* 1982 -1996 Pfizer Inc: Senior Vice President European Medicinal Research
and Development (1992-1996), Senior Vice President and Worldwide Head of
Drug Discovery (1992-1996);
* 1997 - 2002 Bristol-Myers Squibb Company: Chief Scientific Officer and
President of the Pharmaceutical Research Institute, member of the Executive
Committee.
* Nationality: British
* Marital Status: Married
* Age: 57
Cambridge Antibody Technology (CAT)
* CAT is a UK-based biotechnology company using its proprietary technologies
and capabilities in human monoclonal antibodies for drug discovery and drug
development. Based near Cambridge, England, CAT currently employs around 290
people.
* CAT is a leader in the discovery and development of human therapeutic
antibodies and has an advanced proprietary platform technology for rapidly
isolating human monoclonal antibodies using phage display systems. CAT has
extensive phage antibody libraries, currently incorporating more than 100
billion distinct antibodies. These libraries form the basis for the
Company's strategy to develop a portfolio of antibody-based drugs.
* HumiraTM, the leading CAT-derived antibody, isolated and optimised in
collaboration with Abbott, has been approved by the US Food and Drug
Administration for marketing in the US as a treatment for rheumatoid
arthritis. Six further CAT-derived human therapeutic antibodies are at
various stages of clinical trials.
* CAT has alliances with a large number of pharmaceutical and biotechnology
companies to discover, develop and commercialise human monoclonal
antibody-based products. CAT has also licensed its proprietary human phage
antibody libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
* CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised #41m in its IPO in March 1997 and #93m in a secondary offering in
March 2000.
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934.
These forward looking statements are based on numerous assumptions regarding
CAT's present and future business strategies and the environment in which CAT
will operate in the future. Certain factors that could cause CAT's actual
results, performance or achievements to differ materially from those in the
forward looking statements include: market conditions, CAT's ability to enter
into and maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABGGDBUBGGGXC
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024
